Phospho-BCAR1 (Y410) Antibody

What is BCAR1 and what is the significance of Y410 phosphorylation?

BCAR1 (Breast Cancer Anti-estrogen Resistance 1), also known as p130Cas, is a member of the Crk-associated substrate (CAS) family of scaffold proteins. It contains multiple protein-protein interaction domains and numerous serine and tyrosine phosphorylation sites . BCAR1 functions as a docking protein that plays a central coordinating role in tyrosine kinase-based signaling related to cell adhesion . The protein contains several key structural elements: an SH3 domain, a proline-rich domain, a substrate domain with 15 repeats of the YxxP consensus phosphorylation motif for Src family kinases, a serine-rich domain, and a bipartite Src-binding domain .

Phosphorylation at Y410 is particularly significant as it is located within the substrate domain and represents one of the key tyrosine residues phosphorylated upon BCAR1 activation. This specific phosphorylation event is linked to BCAR1's activation and its involvement in promoting tumor growth and metastasis . The Y410 site serves as a critical node in signaling cascades that regulate cell migration, invasion, and survival, making it an important marker for studies on cancer progression and cell motility .

How does the Phospho-BCAR1 (Y410) antibody work in experimental applications?

The Phospho-BCAR1 (Y410) antibody is designed to specifically recognize BCAR1 protein only when phosphorylated at the Y410 residue. These antibodies are typically generated by immunizing rabbits with a synthetic phosphorylated peptide corresponding to the region surrounding Y410 of human BCAR1 . The high specificity comes from the antibody's ability to recognize both the amino acid sequence context and the phosphate group at position Y410.

In Western blot applications, these antibodies bind to the phosphorylated form of BCAR1 in protein samples that have been separated by gel electrophoresis and transferred to a membrane. This binding is then detected using secondary antibodies and appropriate detection systems . The typical dilution range for Western blot applications is 1:500 to 1:2500, depending on the specific antibody formulation and manufacturer .

Most Phospho-BCAR1 (Y410) antibodies have been validated for Western blot and ELISA applications with human and mouse samples, making them versatile tools for comparative studies across these species .

Why is there a discrepancy between calculated and observed molecular weights of BCAR1?

Researchers commonly observe a discrepancy between the calculated molecular weight of BCAR1 (93 kDa) and its apparent molecular weight on Western blots (approximately 140 kDa) . This difference occurs due to several factors:

• Post-translational modifications: BCAR1 undergoes extensive phosphorylation at multiple sites (not just Y410), which can add significant molecular weight and alter protein mobility in SDS-PAGE.

• Structural features: The protein contains domains with unusual amino acid compositions (such as the proline-rich and serine-rich regions) that can cause anomalous migration on gels.

• Glycosylation: Some evidence suggests BCAR1 may undergo glycosylation, further contributing to the higher observed molecular weight.

This discrepancy is well-documented and consistent across different experimental systems. When validating antibody specificity, researchers should expect to observe BCAR1 at approximately 140 kDa rather than at its calculated molecular weight of 93 kDa .

How can I verify the specificity of Phospho-BCAR1 (Y410) antibody in my experimental system?

Verifying antibody specificity is crucial for reliable research outcomes. For Phospho-BCAR1 (Y410) antibodies, consider these validation approaches:

• Phosphatase treatment: Treat one sample with lambda phosphatase before Western blotting. The signal should disappear in the treated sample but remain in untreated controls.

• Competing peptide assay: Pre-incubate the antibody with the phosphorylated peptide used as the immunogen. This should block specific binding and eliminate the signal, as demonstrated in validation studies with the Y762 phospho-site .

• Stimulation/inhibition experiments: Compare samples from cells treated with known inducers of BCAR1 phosphorylation (e.g., pervanadate) versus untreated cells. Western blot analysis shows that pervanadate treatment significantly increases phospho-BCAR1 (Y410) signal in HeLa cells .

• siRNA knockdown: Reduce BCAR1 expression using siRNA and confirm that both the phosphorylated and total BCAR1 signals decrease proportionally.

• Multiple antibody comparison: Use antibodies from different sources or those targeting different phosphorylation sites to confirm consistent patterns of BCAR1 phosphorylation.

The following table summarizes typical validation experiments observed in the literature:

What signaling pathways regulate BCAR1 Y410 phosphorylation?

BCAR1 Y410 phosphorylation is regulated by several interconnected signaling pathways that are crucial for cell adhesion, migration, and cancer progression:

• Integrin-FAK-Src pathway: Upon integrin engagement with the extracellular matrix, Focal Adhesion Kinase (FAK) is activated and recruits Src family kinases, which directly phosphorylate BCAR1 at multiple tyrosine residues, including Y410 .

• Growth factor receptor signaling: Activation of receptor tyrosine kinases (RTKs) like EGFR can initiate signaling cascades leading to BCAR1 phosphorylation, often through Src activation.

• Mechanical stress signaling: Physical forces and mechanotransduction can trigger BCAR1 phosphorylation at Y410 through tension-sensitive complexes at focal adhesions.

• BCAR3-mediated regulation: BCAR3 association with BCAR1 influences its phosphorylation status and is involved in the inhibition of TGFβ signaling .

Researchers can manipulate these pathways experimentally using:

• Src family kinase inhibitors (e.g., PP2, dasatinib)

• FAK inhibitors (e.g., PF-573228)

• Pervanadate (a tyrosine phosphatase inhibitor) to enhance phosphorylation

• Matrix stiffness modulation to study mechanotransduction effects

• Growth factor stimulation or withdrawal

Understanding these regulatory mechanisms is essential for correctly interpreting experimental results and designing appropriate controls when studying BCAR1 Y410 phosphorylation.

How does BCAR1 Y410 phosphorylation contribute to cancer progression?

BCAR1 Y410 phosphorylation plays multiple critical roles in cancer progression through several mechanisms:

• Enhanced cell migration and invasion: Phosphorylated BCAR1 activates downstream effectors that promote cytoskeletal reorganization, lamellipodia formation, and focal adhesion turnover - all essential processes for cancer cell migration and invasion .

• Antiestrogen resistance: BCAR1 was originally identified as a protein that, when overexpressed, confers resistance to antiestrogen therapies in breast cancer. Phosphorylation at Y410 contributes to this resistance mechanism by activating alternative survival pathways .

• Cell survival and proliferation signaling: Phosphorylated BCAR1 activates multiple pro-survival pathways, including PI3K/AKT and MAPK cascades, promoting cancer cell survival and proliferation even under therapeutic pressure .

• Metastatic potential: The activation of migration-related pathways through Y410 phosphorylation directly contributes to the metastatic capability of cancer cells .

• Interaction with other oncogenic pathways: Phosphorylated BCAR1 can interact with multiple signaling nodes, creating feedback loops that amplify oncogenic signaling networks .

These mechanisms make phospho-BCAR1 (Y410) an important biomarker and potential therapeutic target in cancer research, particularly in studies focused on metastasis and therapy resistance.

What are optimal sample preparation conditions for detecting phospho-BCAR1 (Y410)?

Preserving phosphorylation status during sample preparation is critical for accurate detection of phospho-BCAR1 (Y410). Follow these methodological guidelines:

• Lysis buffer composition:

  • Use RIPA or NP-40 based buffers containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Include protease inhibitor cocktail

  • Maintain cold temperature (4°C) throughout processing

• Cell treatment prior to lysis:

  • For positive controls, treat serum-starved cells with pervanadate (1mM) for 30 minutes

  • Rapid processing is essential after stimulation to capture transient phosphorylation events

• Sample handling:

  • Keep samples on ice at all times

  • Avoid repeated freeze-thaw cycles

  • Process samples immediately after collection when possible

• Loading controls:

  • Include both total BCAR1 antibody and phosphorylation-independent loading controls (β-actin, GAPDH)

  • Consider using phospho-specific loading controls for normalization of general phosphorylation status

• Blocking optimization:

  • Use 3-5% BSA in TBS-T rather than milk (which contains phosphatases)

  • For high background, consider specialized blocking reagents designed for phospho-epitopes

Following these methodological steps will significantly improve detection sensitivity and reproducibility when working with phospho-BCAR1 (Y410) antibodies.

What are common troubleshooting approaches for Western blot using phospho-BCAR1 (Y410) antibody?

When working with phospho-BCAR1 (Y410) antibody in Western blot applications, researchers may encounter several challenges. Here are methodological solutions to common problems:

• Weak or no signal:

  • Increase antibody concentration (try 1:500 instead of 1:2000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Enhance stimulation of cells (increase pervanadate concentration or treatment time)

  • Use enhanced chemiluminescence (ECL) detection systems with higher sensitivity

  • Ensure phosphatase inhibitors were properly included in all buffers

• High background:

  • Increase blocking time and concentration (5% BSA for 2 hours)

  • Add 0.05-0.1% Tween-20 to antibody dilution buffer

  • Increase washing steps (5 washes of 5 minutes each)

  • Decrease secondary antibody concentration

  • Use freshly prepared buffers

• Multiple bands/non-specific binding:

  • Increase antibody specificity by using competing non-phosphorylated peptide

  • Optimize gel percentage to better resolve proteins in the 140 kDa range

  • Use gradient gels for improved separation

  • Consider using alternative detection methods (e.g., fluorescent secondary antibodies)

• Inconsistent results between experiments:

  • Standardize lysate preparation methods

  • Use consistent cell densities and treatment conditions

  • Prepare master mixes of antibody dilutions

  • Include positive control samples (e.g., pervanadate-treated HeLa cells)

These methodological approaches address the technical challenges specific to phospho-epitope detection and will help improve reproducibility when working with phospho-BCAR1 (Y410) antibodies.

How can I quantitatively assess changes in BCAR1 Y410 phosphorylation?

Quantitative assessment of phospho-BCAR1 (Y410) requires rigorous methodology to ensure accurate comparisons between experimental conditions. Consider these approaches:

• Normalization strategies:

  • Always normalize phospho-BCAR1 (Y410) to total BCAR1 protein rather than housekeeping genes alone

  • Use appropriate loading controls (β-actin, GAPDH) to verify equal protein loading

  • Consider dual detection systems (fluorescent secondaries with different wavelengths) for simultaneous detection of phospho and total protein

• Densitometric analysis:

  • Use software packages (ImageJ, Image Studio, etc.) that can perform background subtraction

  • Define consistent region of interest (ROI) boundaries across all samples

  • Generate standard curves using dilution series of positive control samples

  • Report results as phospho/total ratios rather than absolute values

• Alternative quantification methods:

  • Consider ELISA-based approaches for higher throughput and better quantification

  • Phospho-protein arrays can assess multiple phosphorylation sites simultaneously

  • Mass spectrometry offers absolute quantification of phosphorylation stoichiometry

• Statistical analysis:

  • Perform experiments with sufficient biological replicates (minimum n=3)

  • Use appropriate statistical tests based on data distribution

  • Report fold-changes relative to control conditions

• Dynamic measurements:

  • Consider time-course experiments to capture the kinetics of phosphorylation

  • Compare EC50 values of different stimuli rather than single time-point measurements

Following these methodological guidelines will enable more reliable quantitative comparisons of BCAR1 Y410 phosphorylation between experimental conditions.

How does BCAR1 Y410 phosphorylation differ from other phosphorylation sites?

BCAR1 contains multiple phosphorylation sites that have distinct but interconnected functions in signaling. Understanding these differences is crucial for comprehensive analysis:

The phosphorylation of Y410 should be considered within this broader context of multi-site phosphorylation. Key methodological considerations include:

• The substrate domain contains 15 YxxP motifs that can be phosphorylated, creating potential for recognition by multiple SH2 domain-containing proteins.

• Different phosphorylation sites may be regulated by distinct upstream signals and have different temporal dynamics.

• Antibodies targeting specific phosphorylation sites (like Y410 or Y762) allow researchers to distinguish between these different signaling events .

• Some sites may exhibit hierarchical phosphorylation, where phosphorylation at one site influences the likelihood of phosphorylation at other sites.

When designing experiments to study BCAR1 phosphorylation, researchers should consider using multiple phospho-specific antibodies to gain a more complete understanding of the signaling dynamics.

What model systems are most appropriate for studying BCAR1 Y410 phosphorylation?

Selecting appropriate model systems is crucial for meaningful investigation of BCAR1 Y410 phosphorylation. Consider these methodological approaches based on research objectives:

• Cell line selection:

  • HeLa cells: Commonly used and validated for phospho-BCAR1 (Y410) studies

  • A431 cells: Demonstrate good phosphorylation response to pervanadate treatment

  • Breast cancer cell lines (MCF-7, MDA-MB-231): Relevant for studying antiestrogen resistance mechanisms

  • Mouse embryonic fibroblasts (MEFs): Useful for genetic manipulation studies

• Primary cells:

  • Human or mouse endothelial cells: Important for studying BCAR1's role in angiogenesis

  • Primary tumor cells: Provide greater clinical relevance than established cell lines

  • Immune cells: For investigating BCAR1's role in immune signaling

• Animal models:

  • BCAR1 knockout mice: For understanding systemic effects (note: complete knockout is embryonic lethal)

  • Conditional tissue-specific knockouts: Better for studying tissue-specific functions

  • Phospho-mutant models (Y410F): To specifically assess the role of Y410 phosphorylation

• 3D culture systems:

  • Spheroids or organoids: Better recapitulate in vivo cellular architecture

  • Matrix invasion assays: Particularly relevant for studying BCAR1's role in invasion and migration

  • Extracellular matrix of varying stiffness: To study mechanotransduction effects on BCAR1 phosphorylation

Each model system has strengths and limitations that should be considered based on the specific research question being addressed. Multi-model approaches often provide the most comprehensive understanding of BCAR1 Y410 phosphorylation biology.

How can I integrate phospho-BCAR1 (Y410) analysis with broader signaling pathway studies?

Integrating phospho-BCAR1 (Y410) analysis into comprehensive signaling studies requires thoughtful methodological approaches:

• Multiplex analysis strategies:

  • Use multiplexed Western blotting with different fluorescent secondaries

  • Consider phospho-protein arrays that can detect multiple phosphorylation events simultaneously

  • Implement mass spectrometry-based phosphoproteomics for unbiased analysis

• Pathway integration approaches:

  • Analyze key upstream regulators (Src, FAK) and downstream effectors (Crk, Dock180) in parallel

  • Monitor multiple branches of signaling cascades (PI3K/AKT, MAPK, RAC/CDC42)

  • Consider temporal dynamics using time-course experiments

• Bioinformatic analysis methods:

  • Implement pathway enrichment analysis of phosphoproteomic data

  • Use protein-protein interaction networks to identify key nodes

  • Apply machine learning approaches to identify patterns in complex signaling data

• Functional correlation strategies:

  • Correlate phosphorylation changes with phenotypic outcomes (migration, invasion, survival)

  • Use inhibitor panels to dissect pathway dependencies

  • Implement genetic approaches (CRISPR, siRNA) targeting multiple pathway components

• Validation in multiple contexts:

  • Compare signaling in 2D vs. 3D culture systems

  • Validate key findings across multiple cell types

  • Correlate in vitro findings with in vivo or clinical samples

By implementing these methodological approaches, researchers can place BCAR1 Y410 phosphorylation in its proper context within the broader signaling network, leading to more comprehensive understanding of its functional significance in normal and pathological conditions.

What are emerging research areas involving phospho-BCAR1 (Y410)?

Current research is expanding our understanding of BCAR1 Y410 phosphorylation beyond its established roles in cancer and cell migration. Emerging areas include:

• Therapeutic targeting: Development of specific inhibitors targeting the BCAR1 signaling axis as potential cancer therapeutics, particularly for overcoming resistance to existing therapies.

• Biomarker development: Exploration of phospho-BCAR1 (Y410) as a biomarker for cancer progression, metastatic potential, or treatment response prediction.

• Mechanobiology integration: Investigation of how mechanical forces regulate BCAR1 phosphorylation and how this contributes to cellular responses to the physical microenvironment.

• Immune signaling roles: Emerging evidence suggests BCAR1 may play important roles in immune cell signaling and function, opening new avenues for immunotherapy research.

• Systems biology approaches: Application of computational modeling to understand how BCAR1 serves as a signal integration hub within complex cellular networks.

These emerging areas represent promising directions for researchers interested in the fundamental biology of BCAR1 signaling and its translational applications in disease contexts.

What methodological advances are improving phospho-BCAR1 (Y410) research?

Recent technological and methodological advances are enhancing our ability to study phospho-BCAR1 (Y410) with greater precision and contextual understanding:

• Advanced imaging techniques:

  • Super-resolution microscopy allowing visualization of BCAR1 within focal adhesion complexes

  • Live-cell imaging with phospho-specific biosensors to monitor real-time phosphorylation dynamics

• Single-cell analysis methods:

  • Single-cell phosphoproteomics revealing cell-to-cell variability in BCAR1 phosphorylation

  • Mass cytometry (CyTOF) for high-dimensional analysis of signaling states

• Genetic engineering approaches:

  • CRISPR-Cas9 genome editing to create specific phospho-site mutants

  • Optogenetic tools to achieve temporal control of pathway activation

  • Proximity labeling techniques to identify context-specific interaction partners

• Computational analysis innovations:

  • Machine learning algorithms for pattern recognition in complex signaling data

  • Network analysis tools for positioning BCAR1 within broader signaling networks

  • Predictive modeling of phosphorylation dynamics